Lynparza™ (olaparib) – Product discontinuation

- On August 28, 2018, the FDA announced the permanent discontinuation of AstraZeneca's Lynparza (olaparib) 50 mg capsules.
    - The discontinuation is not due to any safety, efficacy or quality issues.
    - The planned permanent discontinuation of Lynparza capsules from the U.S. market was August 31, 2018.
    - Lynparza 100 mg and 150 mg tablets will continue to be available.

- Lynparza capsules and tablets are indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

- In addition, Lynparza tablets are also indicated for the following:
    - Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
    - In patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

- Do not substitute Lynparza capsules (50 mg) with Lynparza tablets (100 mg and 150 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.